Cargando…

Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease

BACKGROUND/AIMS: Exclusive enteral nutrition (EEN), an established modality for pediatric Crohn’s disease (CD) is seldomly utilized in adults. The present study reports the outcome of EEN in adult CD patients at a tertiary care hospital in India. METHODS: This was a retrospective analysis of CD pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Sanchit, Gupta, Arti, Kedia, Saurabh, Agarwal, Samagra, Singh, Namrata, Goyal, Sandeep, Jain, Saransh, Gupta, Vipin, Sahu, Pabitra, Vuyyuru, Sudheer Kumar, Kante, Bhaskar, Sharma, Raju, Panwar, Rajesh, Sahni, Peush, Makharia, Govind, Ahuja, Vineet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322023/
https://www.ncbi.nlm.nih.gov/pubmed/32447877
http://dx.doi.org/10.5217/ir.2019.09172
Descripción
Sumario:BACKGROUND/AIMS: Exclusive enteral nutrition (EEN), an established modality for pediatric Crohn’s disease (CD) is seldomly utilized in adults. The present study reports the outcome of EEN in adult CD patients at a tertiary care hospital in India. METHODS: This was a retrospective analysis of CD patients who received EEN as a sole modality/adjunct to other treatment. The primary and secondary outcomes changed in Crohn’s Disease Activity Index (CDAI), and clinical response (decline in CDAI > 70), respectively, at 4 and 8 weeks. Subgroup analysis evaluated response across different phenotypes, EEN formulations and prior treatment. Linear mixed effect model was created to assess the predictors of EEN response. RESULTS: Thirty-one CD patients received EEN over median duration of 4 weeks (range, 2–6 weeks). CDAI showed a significant improvement post EEN at 4 (baseline 290 [260–320] vs. 240 [180–280], P=0.001) and 8 weeks (baseline 290 [260–320] vs. 186 [160–240], P=0.001), respectively. The cumulative clinical response rates at 4 and 8 weeks were 37.3% and 80.4% respectively. The clinical response rates at 8 weeks across B1 (n = 4), B2 (n = 18) and B3 (n = 9) phenotypes were 50%, 78.8% and 100% respectively (log-rank test, P=0.093). The response rates at 8 weeks with polymeric (n = 8) and semi-elemental diet (n = 23) were 75% and 82.6%% respectively (log-rank test, P=0.49). Baseline CDAI (odds ratio, 1.008; 95% confidence interval, 1.002–1.017; P=0.046) predicted response to EEN. CONCLUSIONS: EEN was effective in inducing clinical response across different phenotypes of CD. Baseline disease activity remained the most important predictor of clinical response to EEN.